Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial

Core Insights - Structure Therapeutics Inc. (NASDAQ:GPCR) achieved a new 52-week high following positive topline results from its clinical program for the obesity treatment candidate, aleniglipron [1][3] - The stock price surged to $94.90 during intra-day trading, ultimately closing at $69.98, reflecting a 102.49% increase [2] - Patients receiving a 120mg daily dose of aleniglipron experienced an 11.3% weight loss over 36 weeks, while those on a 240mg dose lost up to 15.3% [2] Clinical Trial Progress - Aleniglipron showed a tolerability profile consistent with GLP-1 receptor agonists and a favorable off-target safety profile [3] - Structure Therapeutics plans to advance to Phase 3 of the clinical trial by mid-2026, following discussions with the FDA in the first half of next year to finalize the trial design [4][5] - The Phase 3 trial is expected to start with a titration dose of 2.5 mg, evaluating multiple doses up to 240 mg [4] Strategic Outlook - The CEO of Structure Therapeutics, Raymond Stevens, emphasized the potential of aleniglipron to become a foundational oral therapy for obesity, highlighting its accessibility, scalability, and combinability [5]